Picture loading failed.

Anti-PCSK9 therapeutic antibody (Pre-made Bococizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Bococizumab (USAN; development code RN316) is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol. Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders."

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-077-1mg 1mg 3090
GMP-Bios-ab-077-10mg 10mg 21890
GMP-Bios-ab-077-100mg 100mg 148000
GMP-Bios-ab-077-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-PCSK9 therapeutic antibody (Pre-made Bococizumab biosimilar,Whole mAb)
INN Name Bococizumab
TargetPCSK9
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusDiscontinued
100% SI Structure3sqo:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2013
Year Recommended2014
CompaniesHalozyme Therapeutics;Pfizer
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedCardiovascular disorders;Hypercholesterolaemia;Hyperlipidaemia
Development Techna